top of page
Search

Virios Therapeutics Announces Initial FDA Feedback On Proposed IMC-1 Phase 3 Program For Treatment o

Virios Therapeutics Announces Initial FDA Feedback On Proposed IMC-1 Phase 3 Program For Treatment of Fibromyalgia; Says Final Toxicology Results To Be Submitted To FDA In

May 2023

 
 
 

Comentários


bottom of page